The FDA on August 16 granted breakthrough designation to CVRx Inc.’s Barostim Neo System, a device meant to improve heart failure symptoms in patients unsuited for other therapies like CRT.
A machine learning algorithm dubbed “MI3” can reportedly predict a person’s risk of heart attack with more nuance than existing algorithms, prompting its developers to claim it as “one of the first effective demonstrations” of how AI can be used to inform treatment decisions in the cardiology unit.
Advances in diabetes care over the past decade haven’t translated into better patient outcomes, researchers at Massachusetts General Hospital have found, with just one in four U.S. adults with the disease meeting treatment goals between 2005 and 2016.
“Silent” strokes are more common than overt strokes in older patients undergoing elective non-cardiac surgery, investigators with the NeuroVISION study have found.
The FDA has expanded its indication for TAVR to low-risk patients, the agency announced August 16, approving a handful of valves for an intervention that was previously limited to intermediate- and high-risk patients.
A combination of 107 chest compressions per minute at a depth of 4.7 centimeters is the optimal CCR-CCD (chest compression rate-chest compression depth) ratio for survival after an out-of-hospital cardiac arrest, researchers reported August 14 in JAMA Cardiology.
Mental illnesses including developmental and mood disorders are prevalent in adolescents and adults with CHD, an American Journal of Cardiology study found, suggesting mental health care might be a beneficial factor in comprehensive treatment.
Biopharmaceutical company Renovacor, Inc., on August 14 announced it had raised $11 million in Series A financing to further develop its gene therapy-based treatments for CVD.
